β Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (464) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ’ Press Releases
Date | Press release |
---|---|
2025-05-30 05:45:00 | Levi & Korsinsky Reminds Shareholders Of A Lead Plaintiff Deadline Of June 3, 2025 In Cerevel Therapeutics Holdings, Inc. Lawsuit - Abbv New york , may 30, 2025 /prnewswire/ -- levi & korsinsky, llp notifies investors in cerevel therapeutics holdings, inc. (βcerevel therapeutics holdings, inc.β or the βcompanyβ) (nyse: abbv) of a class action securities lawsuit. class definition: the lawsuit seeks to recover losses on behalf of cerevel therapeutics holdings, inc. investors who were adversely affected by alleged securities fraud. |
2025-05-29 12:22:00 | Contact The Gross Law Firm By June 3, 2025 Deadline To Join Class Action Against Cerevel Therapeutics Holdings, Inc.(abbv) New york, may 29, 2025 (globe newswire) -- the gross law firm issues the following notice to shareholders of cerevel therapeutics holdings, inc. (nyse: abbv). |
2025-05-29 05:45:00 | Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (abbv) Seeking Recovery For Investors - Contact The Gross Law Firm New york , may 29, 2025 /prnewswire/ -- the gross law firm issues the following notice to shareholders of cerevel therapeutics holdings, inc. (nyse: abbv). shareholders who purchased shares of abbv during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. |
2025-05-27 09:15:00 | Lost Money On Cerevel Therapeutics Holdings, Inc. (abbv)? Urged To Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky New york, ny / access newswire / may 27, 2025 / if you suffered a loss on your cerevel therapeutics holdings, inc. (nyse:abbv) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=150335&wire=1&utm_campaign=22 or contact joseph e. levi, esq. |
2025-05-27 09:00:00 | Abbvie Features New Data Across Difficult-to-treat Solid Tumors And Blood Cancers At Asco 2025, Highlighting Breadth And Depth Of Its Oncology Portfolio -Β Β key oral presentations highlight new data from abbvieβs novel investigational antibody-drug conjugates (adcs) including telisotuzumab adizutecan (abbv-400, temab-a) in advanced non-small cell lung cancer (nsclc), abbv-706 in high-grade neuroendocrine neoplasms (nens) and pivekimab sunirine (pvek) in blastic plasmacytoid dendritic cell neoplasm (bpdcn). north chicago, ill. |
2025-05-27 07:30:00 |
|
2025-05-23 05:45:00 |
|
2025-05-22 13:47:00 |
|
2025-05-22 05:45:00 |
|
2025-05-21 13:20:00 |
|
2025-05-21 07:25:00 |
|
2025-05-20 05:45:00 |
|
2025-05-19 13:30:00 |
|
2025-05-19 13:04:00 |
|
2025-05-19 07:30:00 |
|

π° Browse additional press releases for AbbVie!
Sign up for free or log inπ Donβt miss "The Checklist Value Investor β A Smarter Way to Pick Stocks" β free!